FDA’s Psychiatric Division Has Rejected Cortex’s Request To Study CX717 In Phase IIb ADHD Study
Cortex Pharmaceuticals, Inc (AMEX:COR) was informed recently that the Food and Drug Administration (FDA) would soon be sending it formal notice that the agency would not approve Cortex’s Investigational New Drug Application for a Phase IIb study of CX717 in attention deficit hyperactivity disorder, or ADHD. The denial is based on results of animal toxicology studies filed by Cortex. [click link for full article]
More: continued here
Filed under: ADHD on October 20th, 2007